Advances in Hematological Disorders: New Insights and Novel Methods
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: closed (10 January 2024) | Viewed by 678
Special Issue Editors
Interests: molecular medicine; epigenetics; gene expression; biotechnology; chromatin architecture
Interests: myelodysplastic syndromes; multiple myeloma; lymphoproliferative disorders; chronic myeloproliferative neoplasms; erythropoiesis; iron metabolism; thalassemia; gaucher disease
Special Issues, Collections and Topics in MDPI journals
2. Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain P.O. Box 15551, United Arab Emirates
3. Clinical Bioinformatics Unit, Department of Pathology, School of Medicine and Health Sciences, Erasmus University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
Interests: pharmacogenomics; personalized therapeutics; clinical care; clinical implementation; clinical studies; pharmacogenomic testing; health technoloigy assessment; regulatory guidance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematological disorders, either congenital or acquired, are usually heterogeneous and mainly driven by genetic mutations and/or epigenetic alterations. Decoding the molecular pathogenesis, investigating the shifted genetic/epigenetic mechanisms and regulating differential gene and non-coding RNA transcripts’ expression may help to determine better risk stratification tools and minimal residual disease profiles. New advanced technologies ensure the accurate quantification of molecular components, underlying the pathogenesis and progression of hematological disorders. However, the distance between advanced technologies and applications in daily clinical practice is currently unbridgeable, due to the high cost and complexity of molecular diagnostic procedures. Precise molecular diagnosis, the recognition of crucial molecular targets for each disorder and the discovery of effective targeted therapeutic agents, are of significant importance and may improve all aspects of clinical practice, including prognosis, diagnosis and prediction of response to specific treatments, as well as the design of personalized treatment approaches for all types of patients.
Dr. Argyro Sgourou
Prof. Dr. Argiris S. Symeonidis
Prof. Dr. George P. Patrinos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematological disorders
- diagnosis
- mutations
- epigenome
- treatment
- response biomarkers
- advanced technologies
- molecular targets
